CO6351740A2 - Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido - Google Patents

Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido

Info

Publication number
CO6351740A2
CO6351740A2 CO11032140A CO11032140A CO6351740A2 CO 6351740 A2 CO6351740 A2 CO 6351740A2 CO 11032140 A CO11032140 A CO 11032140A CO 11032140 A CO11032140 A CO 11032140A CO 6351740 A2 CO6351740 A2 CO 6351740A2
Authority
CO
Colombia
Prior art keywords
macrociclic
hcv
nucleoside
inhibitor
synergic combinations
Prior art date
Application number
CO11032140A
Other languages
English (en)
Inventor
Tse-I Lin
Oliver Lenz
Original Assignee
Ortho Mcneil Janssen Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm Inc filed Critical Ortho Mcneil Janssen Pharm Inc
Publication of CO6351740A2 publication Critical patent/CO6351740A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con una combinación sinérgica del compuesto de la fórmula (I):o una de sus sales farmacéuticamente aceptables, y el compuesto de la fórmula (II):o una de sus sales farmacéuticamente aceptables.
CO11032140A 2008-09-18 2011-03-15 Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido CO6351740A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08164612 2008-09-18

Publications (1)

Publication Number Publication Date
CO6351740A2 true CO6351740A2 (es) 2011-12-20

Family

ID=40076811

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11032140A CO6351740A2 (es) 2008-09-18 2011-03-15 Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido

Country Status (20)

Country Link
US (1) US20110171174A1 (es)
EP (1) EP2341907A1 (es)
JP (1) JP2012502956A (es)
KR (1) KR20110054056A (es)
CN (1) CN102164602A (es)
AP (1) AP2011005608A0 (es)
AR (1) AR073603A1 (es)
AU (1) AU2009294622A1 (es)
BR (1) BRPI0919404A2 (es)
CA (1) CA2737835A1 (es)
CO (1) CO6351740A2 (es)
EA (1) EA201170456A1 (es)
EC (1) ECSP11010902A (es)
IL (1) IL211599A0 (es)
MX (1) MX2011002896A (es)
PA (1) PA8842901A1 (es)
TW (1) TW201023858A (es)
UY (1) UY32128A (es)
WO (1) WO2010031829A1 (es)
ZA (1) ZA201102047B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
WO2010033443A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
SG184524A1 (en) * 2010-04-13 2012-11-29 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
MX2013003060A (es) * 2010-09-30 2013-05-30 Boehringer Ingelheim Int Terapia de combinacion para tratar infeccion por hcv.
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR102168621B1 (ko) * 2012-12-21 2020-10-22 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2018017989A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination therapy regimen for treatment of selected hcv genotypes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2641859A1 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
AR059430A1 (es) * 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
JP2010505902A (ja) * 2006-10-10 2010-02-25 メディヴィル・アクチエボラーグ Ｈｃｖヌクレオシド阻害剤

Also Published As

Publication number Publication date
WO2010031829A1 (en) 2010-03-25
AU2009294622A1 (en) 2010-03-25
TW201023858A (en) 2010-07-01
EP2341907A1 (en) 2011-07-13
US20110171174A1 (en) 2011-07-14
AP2011005608A0 (en) 2011-04-30
EA201170456A1 (ru) 2011-08-30
MX2011002896A (es) 2011-08-15
ZA201102047B (en) 2012-08-29
BRPI0919404A2 (pt) 2015-12-15
UY32128A (es) 2010-03-26
AR073603A1 (es) 2010-11-17
CN102164602A (zh) 2011-08-24
PA8842901A1 (es) 2010-04-21
JP2012502956A (ja) 2012-02-02
KR20110054056A (ko) 2011-05-24
ECSP11010902A (es) 2011-06-30
CA2737835A1 (en) 2010-03-25
IL211599A0 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
CO6351740A2 (es) Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
UY32730A (es) Inhibidores de cyp17
CU20090017A7 (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
RS54386B1 (en) ANTIVIRAL UNITS
CR20120397A (es) Inhibidores del virus de la hepatitis c
CU24099B1 (es) Derivados de sulfonamida para el tratamiento del dolor
PA8850801A1 (es) Compuestos útiles para inhibir chk1
NI201100049A (es) Compuestos orgánicos.
HN2011000209A (es) Compuestos macrociclicos de quinoxalina como inhibidores de la proteasa ns3 de vhc
CO6300942A2 (es) Piridinas y pirazinas como inhibidores de p13k
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
AR077765A1 (es) Inhibidores de los virus flaviviridae
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
EA201070786A1 (ru) Бензофуропиримидиноны
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
CY1110648T1 (el) Ενωσεις τροπανιου
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
CR20110219A (es) Ácidos naftilacéticos
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
CR20110264A (es) Pirazolilaminopiridinas como inhibidores de fak
PA8793201A1 (es) Pirimidinas bicíclicas fusinadas
UY30476A1 (es) Noveles compuestos derivados n-sustituidos de la 3-oxoisoindolin-1-carboxamida, sus sales aceptables, composiciones farmaccuticas y aplicaciones.
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90

Legal Events

Date Code Title Description
FA Application withdrawn